Hyloris announced a new licensing agreement with RedHill Biopharma to bring in ex-US rights for ondansetron ER, a serotonin blocker that provides relief from nausea and vomiting with chemotherapy, radiotherapy and post-operative recovery. Meanwhile, the FDA accepted oral liquid valacyclovir's regulatory submission for review with a PDUFA date set for October 12, 2025. We intend to incorporate ondansetron ER in a future update of our model and look forward to the valacyclovir decision, while reit...
Spinal Research UK published the results of a new study with Onward's non-invasive ARC-EX device. Ten patients received 120 sessions of ARC-EX + rehab, showing statistically significant improvements on various endpoints for functional recovery. Improvements did not plateau after 1 year, underlining ARC-EX' game changing potential, we reiterate Buy/€10.4 TP.
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: GREENING, ROVI, TALGO, TELEFÓNICA. EUROPA: ASML. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 4T’24 que se publicarán en España y Europa en los próximos días. EE.UU. arrastra a Europa Pese a la reacción positiva inicial de las bolsas europeas al resultado de las elecciones alemanas, la jornada fue de más ...
ONWARD Medical Announces Publication of One-Year Study Showing Benefit of Sustained Access to ARC-EX Therapy Study shows significant functional improvements after one year of ARC-EX Therapy Improvements were observed throughout one-year treatment period with no plateau Results demonstrate the importance of sustained access to ARC-EX Therapy EINDHOVEN, the Netherlands, Feb. 25, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with s...
ASML reports transactions under its current share buyback program ASML reports transactions under its current share buyback program VELDHOVEN, the Netherlands – ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML's current share buyback program. DateTotal repurchased sharesWeighted average priceTotal repurchased value17-Feb-2589,290€725.89€64,814,74518-Feb-2589,696€722.60€64,814,50019-Feb-2590,675€714.80€64,814,21820-Feb-2590,498€716.20€64,814,49621-Feb-2591,095€711.50€64,814,229 ASML’s current share buyback program was announced on 10 November 2022, and detai...
ASML reports transactions under its current share buyback program ASML reports transactions under its current share buyback program VELDHOVEN, the Netherlands – ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML's current share buyback program. DateTotal repurchased sharesWeighted average priceTotal repurchased value10-Feb-2590,797713.8464,814,66711-Feb-2589,734722.2964,814,41112-Feb-2590,383717.1164,814,19213-Feb-2589,036727.9664,814,33514-Feb-2587,862737.6964,814,523 ASML’s current share buyback program was announced on 10 November 2022, and details are ava...
Hyloris announced that it has entered into an exclusive licensing agreement to develop a ready-to-use formulation for intravenous (IV) administration of pantoprazole (proton pump inhibitor, PPI) to treat gastric acid-related conditions. According to management, there is limited clinical development required as the efficacy of the reference drug has already been established, and Hyloris expects to enter the first markets (likely US and EU) in 3 years. Note that according to guidance from the 1H24...
ABN AMRO: Strong results ex one-off, capital, cautious outlook. Ahold Delhaize: FY25F outlook calls for consensus downgrade. DEME Group: Preview - FCF machine. Heineken: Nothing missing. Kinepolis: Canadian peer Cineplex 4Q24 results and Jan 2025 box office revenue. Montea: Good results, guidance reiterated, focus on 2025 investments. Randstad: 4Q24 results beat 3% but key drivers miss, 1Q25 outlook disappoints. Var Energi: Raising outlook and dividend
ASML reports transactions under its current share buyback program ASML reports transactions under its current share buyback program VELDHOVEN, the Netherlands – ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML's current share buyback program. DateTotal repurchased sharesWeighted average priceTotal repurchased value03-Feb-2592,077703.9264,814,41804-Feb-2591,078711.6364,814,28305-Feb-2592,345701.8764,814,45306-Feb-2591,127711.2564,814,36107-Feb-2591,272710.1364,814,639 ASML’s current share buyback program was announced on 10 November 2022, and details are ava...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.